Overview
- Description
The company develops first-in-class therapies for neurodegenerative diseases using homeoprotein-based treatments, with lead candidates targeting ALS, Parkinson’s, and retinal disorders.
- Website
- Country
- France
- Sector
- Health Biotechnology
*By clicking here you will be leaving the official EIC website and you will be directed to the Dealroom.co domain, an official EISMEA contractor for the EIC investor matchmaking platform.